Sacubitril/valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men.

CONCLUSIONS: Sacubitril/valsartan combined with a DPP-4 inhibitor lead to markedly higher concentrations of intact GLP-1 than DPP-4 inhibition alone, supporting a role for both neprilysin and DPP-4 in the metabolism of GLP-1 in humans, a finding which may have therapeutic implications. PMID: 31074791 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31074791?dopt=Abstract

Source: The Journal of Clinical Endocrinology and Metabolism - May 9, 2019 Category: Endocrinology Authors: Wewer Albrechtsen NJ, Mark PD, Terzic D, Hansen LH, Andersen UØ, Hartmann B, Carr RD, Gustafsson F, Deacon CF, Holst JJ, Goetze JP, Plomgaard P Tags: J Clin Endocrinol Metab Source Type: research